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Abstract
Quiescent HIV-1 infection of resting CD4 + T cells is an obstacle to eradication of HIV-1 infection. These res-
ervoirs are maintained, in part, by repressive complexes that bind to the HIV-1 long terminal repeat (LTR) and
recruit histone deacetylases (HDACs). cMyc and YY1 are two transcription factors that are recruited as part of
well-described, distinct complexes to the HIV-1 LTR and in turn recruit HDACs. In prior studies, depletion of
single factors that recruit HDAC1 in various cell lines was sufficient to upregulate LTR activity. We used short
hairpin RNAs (shRNAs) to test the effect of targeted disruption of a single transcription factor on quiescent
proviruses in T cell lines. In this study, we found that depletion of YY1 significantly increases mRNA and protein
expression from the HIV-1 promoter in some contexts, but does not affect HDAC1, HDAC2, HDAC3, or
acetylated histone 3 occupancy of the HIV-1 LTR. Conversely, depletion of cMyc or cMyc and YY1 does not
significantly alter the level of transcription from the LTR or affect recruitment of HDACs to the HIV-1 LTR.
Furthermore, global inhibition of HDACs with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA)
enhanced the increase in LTR transcription in cells that were depleted of YY1.These findings show that despite
prior isolated findings, redundancy in repressors of HIV-1 LTR expression will require selective targeting of
multiple restrictive mechanisms to comprehensively induce the escape of quiescent proviruses from latency.
Introduction
Substantial advances have been made in the treatmentof human immunodeficiency virus (HIV-1) infection.
However, due to the burdens of lifelong antiviral therapy,
attention has recently focused on research directed at eradi-
cation of HIV-1 infection. To accomplish this challenging goal,
techniques to target and eliminate a small population of qui-
escent proviral genomes that persist in infected individuals
undergoing therapy are under study.
The transcription of quiescent proviral genomes is re-
pressed by the presence of mature heterochromatic structures
that are maintained through the recruitment of cellular tran-
scription factors. The quiescent HIV-1 long terminal repeat
(LTR) is occupied by the NURD and the NCoR histone dea-
cetylase (HDAC) complexes in Jurkat and monocyte-derived
macrophage cell lines, respectively.1,2 These HDAC com-
plexes repress transcription by removing acetyl groups from
histones, which results in a repressive chromatin structure at
the HIV-1 LTR that is not permissive for transcription. HDAC
inhibitors are consistently able to reactivate quiescent HIV-1
in cell line models and in patients’ cells.3–6 However, HDACs
regulate the expression of a broad range of cellular factors,
and HDAC inhibitors affect the acetylation of lysines on many
nonhistone proteins. Therefore, the aim of this study was to
determine whether factors that specifically recruit HDACs to
the HIV-1 promoter could be directly targeted to reverse HIV-
1 quiescence. To date, several transcription factors have been
described that recruit HDAC1 to the HIV-1 LTR, including
cMyc, YY1, CBF1, NF-jB, and Sp1.3,7–9 Surprisingly, although
each of these factors binds to the LTR at a distinct location and
individually recruits HDACs, previous studies have found
that single depletion of any one of these factors is sufficient to
disrupt quiescent HIV-1 proviruses and occupancy of
HDAC1 at the HIV-1 promoter. Furthermore, these findings
indicate that in the absence of one HDAC recruiting complex,
HDAC occupancy cannot be maintained at a level sufficient to
prevent reactivation of HIV-1 transcription.
YY1 and cMyc are two transcription factors that are re-
cruited to the HIV-1 promoter and are involved in the main-
tenance of transcriptional repression. YY1 can both activate
and repress transcription depending on the promoter
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context.10 YY1 is recruited to the HIV-1 LTR by the tran-
scription factor LSF and represses transcription by recruiting
HDAC1 in HeLa cells.3,11 cMyc is a transcription factor that is
most commonly known for its roles in regulating cellular
proliferation and cell growth. Like YY1, it is able to act as both
a transcriptional activator and repressor depending on the
context of the promoter.12 The mbIII domain of cMyc is im-
portant for its ability to repress transcription and mediates the
interaction between cMyc and HDAC3.13 cMyc is repressive
when recruited to the HIV-1 LTR by the transcription factor
Sp1.8 However, cMyc is required for Tat activated HIV-1
transcription.14 Because of their well-characterized role in the
maintenance of quiescent HIV, cMyc and YY1 are promising
targets for therapies to disrupt the silencing of integrated
HIV-1 proviruses.
Many of the initial studies that were instrumental in elu-
cidating the mechanisms of HIV-1 transcriptional repression
have been performed in HeLa cell lines. HeLa cells are an
epithelial cell line that was originally isolated from cervical
cancer tissue.15 In vivo, HIV-1 infects CD4 + T cells of the im-
mune system. The cell environment and transcriptional pro-
files of epithelial and T cells are very different. Therefore,
mechanisms that maintain transcriptionally quiescent provi-
ral genomes in T cells are of paramount relevance. Jurkat cells
are a cell line derived from T cells with biochemical features
similar to resting CD4 + T cells. Several cell lines that are de-
rived from Jurkat cells and contain quiescent, but inducible
HIV-1 proviruses have been created as models of HIV-1 la-
tency, including 2D10 and J89 cells.16,17 We performed our
studies in 2D10 and J89 cells because unique proviral insertion
sites, and perhaps subtle differences in cellular gene pro-
gramming, result in widely distinct sensitivity to viral in-
duction strategies. These studies more accurately reflect the
diversity of HIV latency in vivo than those performed in a
single clonal model. The goal of this study was to determine
whether the selective targeting of transcription factors, such
as cMyc and YY1, that recruit HDACs to the LTR and main-
tain transcriptional repression of HIV-1, could disrupt latency
in T cell lines. Furthermore, we wished to determine whether
these factors play a unique or general role in the individual
recruitment of HDAC1, HDAC2, and HDAC3 to the HIV-1
LTR. The mechanisms that maintain proviral quiescence are




J89 (a kind gift from Dr. David Levy at the University of
Alabama at Birmingham) and 2D10 (a kind gift from Dr.
Jonathan Karn at Case Western Reserve University) cells were
maintained in RPMI supplemented with 10% fetal bovine
serum (FBS) and 1% Pen/strep in a 37C incubator containing
CO2. Cells were passaged every 3-4 days, and all experiments
were performed on cells that had been passaged fewer than 12
times. For the experiments in which suberoylanilide hydro-
xamic acid (SAHA, Merck Research Laboratories, West Point,
PA) or phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich,
St. Louis, MO) was used, 500 nM SAHA or 10 nM PMA was
added to the cell media 54 h after transduction with short-
hairpin RNAs (shRNAs) and 18 h prior to collection for flow
cytometry.
Chromatin immunoprecipitation (ChIP) assays
Ten million cells that had been transduced with short
hairpin RNAs (shRNAs) were collected, washed once with
phosphate-buffered saline (PBS), and then fixed with 1%
formaldehyde for 10 min. The cell nuclei were isolated ac-
cording to the manufacture’s instructions and sonicated for
24 min in a bioruptor (Diagenode, Denville, NJ) with intervals
that consisted of 30 s of sonication and 15 s of rest. To bind the
antibodies to the beads, protein A and protein G Dynal beads
(Invitrogen, Grand Island, NY) were incubated with 5–10 lg
of antibody. The following antibodies were used for the ChIP
experiments: HDAC1 ChIP grade (Abcam, Cambridge, MA),
HDAC2 ChIP grade (Abcam, Cambridge, MA), HDAC3 ChIP
grade (Abcam, Cambridge, MA), histone 3 ChIP grade (Ab-
cam, Cambridge, MA), and acetylated histone 3 (Millipore,
Billerica, MA). The sonicated product was then added and
incubated at 4C overnight. The next day, the beads were
washed once for 5 min with each of the following buffers:
ChIP dilution buffer, low salt ChIP buffer, high salt ChIP
buffer, LiCl ChIP buffer, and TE buffer. The samples were
then eluted from the beads and incubated at 68C for 2 h to
decrosslink the proteins from the DNA and to degrade the
protein. The DNA was purified using the Qiagen PCR puri-
fication kit (Qiagen, Valencia, CA) according to the manu-
facturer’s instructions. The enrichment of the HIV-1 LTR in
the ChIP samples was assessed using quantitative PCR
(qPCR). Independent transductions were performed for each
ChIP replicate.
Quantitative PCR
One microliter of the DNA from the ChIP assay was used in
a final volume of 20 ll containing 10 ll of SYBR green master
mix (Applied Biosystems, Foster City, CA) and 0.5 lM each of
the primers LTRrt8 (5¢-TAGCCAGAGAGCTCCCAGGCTC
AGA-3¢) and LTRrt9 (5¢-AGCCCTCAGATGCTACATATAA
GCA-3¢). The reaction was run on a 7900 quantitative PCR
machine (Applied Biosystems, Foster City, CA) with the fol-
lowing parameters: 50C for 2 min; 95.0C for 10 min; and 40
replicates of 95.0C for 15 s and 60C for 1 min. A standard
curve ranging from 50% to 0.0008% of the total ChIP input
was run for each condition, and the data are displayed as the
percent input with the background from the IgG condition
subtracted. Experiments with less DNA than the IgG control
sample were assigned zero quantity. Data are shown as the
mean – standard error of the mean (SEM) from at least three
independent ChIP experiments. The Student’s t-test was used
to assess significance, and a p-value of less than 0.05 was
considered significant.
Quantification of gene expression
2D10 or J89 cells that had been transduced with shRNAs
were collected 72 h after transduction, and RNA was ex-
tracted using the RNeasy mini kit (Qiagen, Valencia, CA). The
RNA was treated with DNase, and then 380 ng of RNA was
reverse transcribed using the SuperScript III First-Strand
synthesis kit (Invitrogen, Grand Island, NY) according to the
manufacturer’s instructions. The reverse transcription quan-
titative polymerase chain reaction assay (RT-qPCR) was
used to determine gene expression. The following primers
and probes were used to amplify the cDNA: Gag-F: 5¢
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ACATCAAGCAGCCATGCAAAT, GAG-R: 5¢ TCTGGCCTG
GTGCAATAGG, GAG FAM PROBE: 5¢ CTATCCCATTCTG
CAGCTTCCTCATTGATG; EGFP-F: 5¢ GGAGCGCACCAT
CTTCTTCA, EGFP-R: 5¢ AGGGTGTCGCCCTCGAA, EGFP
FAM Probe: CTACAAGACCCGCGCCGAGGTG; HDAC1-F:
5¢ TGAGGACGAAGACGACCCT, HDAC1-R: 5¢ CTCACA
GGCAATTCGTTTGTC, and HDAC1 FAM probe: 5¢ CAA
GCGCATCTCGATCTGCTCCTC18; HDAC2-F: 5¢ CTTTCC
TGGCACAGGAGACTT, HDAC2-R: 5¢ CTCATTGGAAAAT
TGACAGCATAGT, and HDAC2 FAM probe: 5¢ AGGGATA
TTGGTGCTGGAAAAGGCAA; and HDAC3-F: 5¢ GGTGGT
TATACTGTCCGAAATGTT, HDAC3-R: 5¢ GCTCCTCACTA
ATGGCCTCTTC, and HDAC3 FAM probe: 5¢ AGCAGCGA
TGTCTCATATGTCCAGCA. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was amplified for each sample and
used for normalization. The primers and probes used were as
follows: GAPDH-F: 5¢ GCACCACCAACTGCTTAGCACC,
GAPDH-R: 5¢ TCTTCTGGGTGGCAGTGATG, and GAPDH
HEX probe: 5¢ TCGTGGGAAGGACTCATGACCACAGTCC.19
Results are displayed as the fold increase over the control
condition, which was calculated using the DDct method. The
values shown represent the mean of three independent experi-
ments – the SEM.
Western blots
J89 or 2D10 cells were collected 72 h after being transduced
with lentiviruses carrying shRNAs. Protein was extracted
with radioimmunoprecipitation assay buffer containing 10 ll
Protease Inhibitor Cocktail (Sigma-Aldrich, St. Louis, MO)
and 10 mM NaF (Sigma-Aldrich, St. Louis, MO). The quantity
of protein was determined using a Bradford protein assay
according to the manufacture’s instructions (Bio-Rad, Her-
cules, CA). Five to ten micrograms of protein was loaded onto
a 4–12% bis-tris gel (Invitrogen, Grand Island, NY). The
western blot was then run as previously described.20 The
following primary antibodies were used: HDAC1, HDAC2,
HDAC3, cMyc, and YY1 (all from Santa Cruz Biotechnology,
Santa Cruz, CA) and alpha tubulin (Abcam, Cambridge, MA)
was used as a loading control. The band intensity of the
western blots was analyzed using Image J software (NIH,
Bethesda, MD). Each western blot was performed using cells
from independent transductions at least three times. The
values shown represent the mean percent protein knock-
down – SEM from three independent experiments.
Transduction of shRNAs
Three million cells were split into 12 ml of RMPI media
containing 10% FBS and 1% pen/strep and incubated over-
night. At 24 h the cells were transduced with lentiviral vectors
carrying cMyc or YY1 shRNAs, and the cells were incubated
at 37C overnight. shRNA plasmids and lentiviruses were
obtained from the UNC Lenti-shRNA core facility, which has
the Open Biosystems shRNA library (Open Biosystems, La-
fayette, CO). The plasmid TRCN0000039642 was used to de-
plete cMyc, and plasmid TRCN0000019898 was used to
deplete YY1. A plasmid containing an shRNA to eGFP was
used as the nonspecific (NS) control in the ChIP experiments
(catalog number RHS4459, Open Biosystems Lafayette, CO).
The pLKO.1 empty vector control (catalog number RHS4080,
Open Biosystems, Lafayette, CO) was used as the negative
control for the RT-qPCR and flow cytometry experiments.
Twenty-four hours after the addition of the shRNA, new
media and 2 lg/ml of puromycin were added to select for
cells that had been transduced. The cells were then incubated
at 37C for 48 h before collection for downstream applications.
New transductions were performed for each experiment, and
cells were never frozen down and thawed for subsequent
experiments. Knockdown was assessed by qPCR and western
blot as described above.
Flow cytometry
Cells were collected 72 h after transduction with lenti-
viruses, washed once with 1 · PBS, and then fixed in 3.2%
paraformaldehyde. The GFP expression of the cells in the
fixed samples was measured using an Attune flow cytometer
(Applied Biosystems, Foster City, CA) or a CyAn ADP ana-
lyzer (Beckman Coulter, Inc., Brea, CA, UNC flow cytometry
core facility). At least 10,000 cells were collected for each
condition. The analysis was performed using FlowJo flow
cytometry analysis software (FlowJo, Ashland, OR).The val-
ues shown are the mean of three independent experi-
ments – SEM from at least three independent experiments.
Results
Depletion of cMyc and YY1 in Jurkat cells
does not affect cell viability
To determine whether cMyc and YY1 are required to
maintain transcriptional repression of the HIV-1 provirus in
Jurkat cells, the RNA interference pathway was used to de-
plete the mRNA transcripts of cMyc and YY1, and the
downstream effects were monitored. Jurkat cells are difficult
to transfect. Therefore, lentiviral vectors were used to trans-
duce plasmids containing shRNAs into Jurkat cell lines to
deplete the transcription factors cMyc and YY1. Transduction
of cMyc-specific shRNAs reduced the amount of cMyc in
2D10 cells by 85% and in J89 cells by 72% (Fig. 1 and data not
shown). Single depletion of YY1 with shRNAs reduced the
amount of YY1 protein by 87% in 2D10 cells and 56% in J89
cells (Fig. 1 and data not shown). Furthermore, the trans-
duction of both cMyc and YY1 shRNAs reduced protein levels
by 57% and 83% in 2D10 cells and by 86% and 62% in J89 cells,
respectively (Fig. 1 and data not shown). The transduced
cells were then selected with puromycin to ensure that the
study population of cells homogenously carried the shRNA-
expressing vector. The CellTiter-Blue cell viability assay
(Promega, Madison, WI) was used to determine the effect of
YY1, cMyc, or YY1 and cMyc depletion on the viability of
Jurkat cells. Transducing Jurkat cells with cMyc, YY1, or cMyc
and YY1 shRNAs does not significantly affect the viability of
2D10 or J89 cells as compared to the cells that were transduced
with the vector control plasmid (Fig. 1d and data not shown).
Therefore, lentivirus transduction of shRNAs is an effective
technique for the depletion of cMyc and YY1 in Jurkat cells
and does not significantly affect cell viability.
Knockdown of the transcription factors cMyc, YY1,
or both does not affect protein or mRNA expression
of HDAC1, HDAC2, or HDAC3
cMyc and YY1 both affect the expression and posttran-
scriptional regulation of a significant number of cellular
genes.10,12 Because cMyc and YY1 are both broadly acting
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transcription factors, it is possible that they could affect HIV-1
transcription by regulating the expression of HDACs. Fur-
thermore, cMyc has recently been shown to regulate the
transcription of HDAC2 in mesenchymal stem cells.21
Therefore, to ensure that the effects of depleting cMyc and
YY1 were not related to an effect on HDAC expression, we
measured the levels of HDAC protein using western blot and
mRNA using RT-qPCR after depletion of cMyc, YY1, or cMyc
and YY1 (Fig. 2). No significant changes in the protein levels
of HDAC1, HDAC2, or HDAC3 were observed by western
blot after knockdown of cMyc, YY1, or cMyc and YY1 in 2D10
or in J89 cells (Fig. 2a and data not shown). Furthermore,
depletion of cMyc, YY1, or cMyc and YY1 did not significantly
affect HDAC1, HDAC2, or HDAC3 mRNA expression when
compared to the cells transduced with the vector control (Fig.
2). Therefore, the effects of depleting cMyc, YY1, or cMyc and
YY1 with shRNAs are not mediated by a secondary depletion
of HDAC1, HDAC2, or HDAC3 in 2D10 or J89 cells (Fig. 2 and
data not shown).
Individual depletion of the transcription factor YY1
significantly increases expression from the HIV-1 LTR
Targeting cMyc or YY1-containing complexes upregulates
expression of HIV-1 mRNA in HeLa cell line models of
HIV-1 latency.8,11,22 To determine whether these transcription
FIG. 1. Depletion of cMyc or YY1 does not affect Jurkat cell viability. Lentiviral shRNAs specific to cMyc, YY1, or cMyc and
YY1 significantly deplete the protein levels of cMyc (a), YY1 (b), or cMyc and YY1 (c) in 2D10 cells as determined by western
blot analysis. (d) Depletion of cMyc, YY1, or cMyc and YY1 does not affect the viability of 2D10 cells 72 h after transduction of
short hairpin RNAs (shRNAs).
FIG. 2. Depletion of cMyc, YY1,
or cMyc and YY1 does not signifi-
cantly affect expression of HDAC1,
HDAC2, or HDAC3 in 2D10 cells.
(a) HDAC1, HDAC2, and HDAC3
protein levels remain stable in 2D10
cells after depletion of cMyc, YY1,
or cMyc and YY1. (b) HDAC1, (c)
HDAC2, or (d) HDAC3 mRNA ex-
pression levels are not significantly
affected by the depletion of cMyc,
YY1, or cMyc and YY1 in 2D10 cells
as measured by the reverse tran-
scription quantitative polymerase
chain reaction (PCR) assay (RT-
qPCR).
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factors are also important for maintaining HIV-1 transcrip-
tional repression in a T cell line, cMyc, YY1, or cMyc and YY1
were depleted from J89 or 2D10 Jurkat T cells, and expression
from the HIV-1 LTR was monitored using RT-qPCR and flow
cytometry. The proviral genomes in both J89 and 2D10 cells
contain GFP, which can be used to monitor expression from
the HIV-1 LTR. In J89 cells, the GFP gene is inserted between
the env and nef genes of the HIV-1 provirus.16 In 2D10 cells,
the GFP gene is inserted between env and the 3¢ LTR and nef is
deleted.17 Additionally, 2D10 cells contain an attenuated tat
and a truncated gag.17 Because the provirus in the 2D10 cells
does not contain the complete gag sequence, we used RT-
qPCR to monitor GFP mRNA expression in the 2D10 cells as a
measure of HIV-1 LTR activity. Following depletion of YY1
from the 2D10 cells there was a significant 4.2-fold increase in
GFP mRNA expression from the HIV-1 LTR (Fig. 3a, p-value
< 0.05). However, GFP mRNA expression did not increase
significantly following depletion of cMyc or both cMyc and
YY1 in the 2D10 cells (Fig. 3a). Furthermore, depletion of
cMyc, YY1, or cMyc and YY1 did not result in a significant
increase in expression of gag mRNA in the J89 cells (Fig. 3c).
To further determine whether the effects seen at the mRNA
level were reflected at the protein level, the percentage of cells
expressing GFP was measured using flow cytometry. The
percentage of 2D10 cells expressing GFP that were depleted of
YY1 significantly increased over 6-fold when compared to the
cells transduced with the vector control, which correlates with
the observed increase in GFP mRNA that was observed
(Fig. 3b, p-value < 0.05). Following knockdown of cMyc or
cMyc and YY1 there was not a significant increase in the
percentage of 2D10 or J89 cells expressing GFP (Fig. 3b and d).
Additionally, no increase in the percentage of J89 cells ex-
pressing GFP was observed following YY1 depletion (Fig. 3d).
Because cMyc and YY1 can both act as transcriptional ac-
tivators as well as repressors, we next determined whether
cMyc or YY1 was required for HIV-1 transcription by adding
PMA to 2D10 or J89 cells that were depleted of YY1, cMyc, or
both for 24 h and measuring the percentage of GFP-positive
cells by flow cytometry. PMA induced a significant percent-
age of cells to express HIV-1-driven GFP over the cells that
were treated with DMSO in the cells depleted of cMyc, YY1, or
cMyc and YY1. Furthermore, there was no significant differ-
ence in the percentage of GFP-positive cells after exposure to
PMA in the cells depleted of cMyc, YY1, or cMyc and YY1 as
compared to the cells transduced with the control shRNA,
which indicates that neither cMyc nor YY1 is required to
induce transcription from the HIV-1 LTR (Supplementary
Fig. S1; Supplementary Data are available online at www
.liebertpub.com/aid).
Together, these results suggest that YY1 is involved in re-
pression of the HIV-1 LTR, but that its effects predominate in
select cellular contexts. The different response of the two cell
lines to YY1 depletion may be due to differences between the
locations of the proviral genomes in these two cell lines or the
degree of repressive chromatin structures that have devel-
oped at the LTR. Furthermore, these results indicate that de-
pletion of cMyc or cMyc and YY1 is not sufficient to induce
expression from the HIV-1 LTR in these Jurkat cell lines.
FIG. 3. Depletion of YY1 signifi-
cantly increases HIV-1 expression
in 2D10 cells. (a) GFP mRNA ex-
pression from the HIV-1 LTR sig-
nificantly increased after depletion
of YY1 from 2D10 cells. No changes
were observed in GFP mRNA ex-
pression levels following depletion
of cMyc or cMyc and YY1 from
2D10 cells. (b) The percentage of
2D10 cells expressing the GFP pro-
tein, as determined by flow cytom-
etry, significantly increased after
depletion of YY1, but not after de-
pletion of cMyc or cMyc and YY1.
(c) Expression of gag mRNA was
not significantly affected by knock-
down of cMyc, YY1, or both in J89
cells. (d) The percentage of J89 cells
expressing the GFP protein, as de-
termined using flow cytometry, did
not significantly increase after
knockdown of cMyc, YY1, or cMyc
and YY1. *p-value of less than 0.05.
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Furthermore, neither cMyc nor YY1 is required for expression
from the HIV-1 LTR. Of relevance to the development of
translational strategies to deplete persistent HIV-1 infection,
these findings demonstrate some redundancy or overlap in
epigenetic mechanisms that maintain proviral latency.
Depletion of cMyc or YY1 does not significantly affect
HDAC occupancy of the HIV-1 LTR
Of the 11 human HDACs, only HDAC1, HDAC2, and
HDAC3 have been shown to play a critical, direct role in the
regulation of HIV-1 LTR expression.20 In HeLa cell lines
containing quiescent proviral genomes, depletion of cMyc or
YY1 leads to transcription from the HIV-1 LTR through de-
pletion of HDAC1 occupancy.8,11 cMyc and YY1 are both
associated with recruitment of HDACs and HDAC complexes
to the LTR of HIV-1 and to the promoters of some cellular
genes.13 Furthermore, HDAC inhibitors are consistently able
to activate HIV-1 transcription in both cell line models and in
patients’ cells.4,5,23 Therefore, the next step of this study was to
determine whether depleting factors that recruit HDACs to
the HIV-1 promoter, cMyc and YY1, had an effect on the re-
cruitment of HDACs to the HIV-1 LTR. Following depletion
of cMyc or YY1, ChIP was used to measure the occupancy of
HDAC1, HDAC2, and HDAC3 in 2D10 and J89 Jurkat cells
(Fig. 4). Depletion of cMyc or YY1 from 2D10 and J89 cells did
not significantly alter HDAC1, HDAC2, or HDAC3 occu-
pancy of the HIV-1 LTR (Fig. 4). Although cMyc and YY1 are
known to interact with HDACs and HDAC complexes, this
result indicates that depletion of these factors is not sufficient
to measurably block HDAC recruitment to the HIV-1 LTR in
these Jurkat cell lines. This finding is consistent with earlier
results that found that depletion of cMyc or cMyc and YY1 did
not significantly affect HIV-1 expression from these cell lines.
However, the lack of change in HDAC occupancy of the
HIV-1 LTR following depletion of YY1 suggests that the
induction of HIV-1 transcription after YY1 knockdown is in-
duced by an effect that does not affect HDAC occupancy at
the HIV-1 promoter.
Acetylation of histone 3 increases at the promoters of acti-
vated genes, and given sufficient gene expression and chro-
matin remodeling, H3 histone occupancy may decrease.24,25
Therefore, to further examine the landscape of the HIV-1 LTR
following depletion of cMyc, YY1, or cMyc and YY1 the oc-
cupancy of histone 3 and acetylated histone 3 was assessed.24
A significant increase in histone acetylation was observed
following depletion of cMyc in 2D10 cells (Fig. 5b, p-value
< 0.05). This upregulation in histone acetylation was not ac-
companied by a significant increase in HIV-1 expression or a
significant change in HDAC occupancy of the HIV-1 LTR. No
significant changes in histone acetylation were observed in J89
cells following cMyc depletion or in either cell line following
YY1 depletion (Fig. 5). The lack of change in histone 3 acety-
lation at the HIV-1 LTR following YY1 depletion is surprising
given the increase in mRNA expression that was observed
and indicates that depletion of YY1 alone is sufficient to dis-
rupt repression of the HIV-1 LTR even in the presence of
HDACs. The lack of change in HDAC occupancy following
FIG. 4. Histone deacetylase (HDAC) occupancy of the HIV-1 promoter is not affected by depletion of cMyc or YY1. (a)
HDAC1, (b) HDAC2, and (c) HDAC3 occupancy of the HIV-1 promoter was not significantly altered after depletion of cMyc
or YY1 from 2D10 cells, as determined using a ChIP assay. (d) HDAC1, (e) HDAC2, and (f) HDAC3 occupancy of HIV-1 LTR
did not change significantly after depletion of cMyc or YY1 from J89 cells as measured by ChIP assay.
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selective disruption of the YY1/LSF complex or the cMyc/Sp1
complex indicates that other factors are present at the HIV-1
LTR that are able to recruit HDACs in the absence of these
complexes.8,11
Depletion of cMyc and YY1 does not affect quiescent
HIV-1 expression in Jurkat cells
Given the possibility that LTR quiescence is maintained by
redundant systems capable of recruiting HDACs to the HIV-1
LTR, both cMyc and YY1 were depleted from J89 and 2D10
cells. However, after knockdown of both cMyc and YY1, there
was not a significant increase in HIV-1 mRNA expression in
J89 or 2D10 cells (Fig. 3a and b). Correspondingly, there was
not a significant change in the percentage of cells expressing
GFP following depletion of both factors from either cell line
(Fig. 3c and d). Therefore, depletion of these two HDAC re-
cruiting factors is not sufficient to disrupt the maintenance of
quiescent HIV.
Furthermore, after depletion of both cMyc and YY1 there
was not a significant change in the occupancy of HDAC1,
HDAC2, or HDAC3 at the HIV-1 LTR as measured by ChIP
assay (Fig. 6). This suggests that derepression of the HIV-1
LTR in T cell lines, unlike in HeLa cells, may require targeting
of additional or different transcription factors. Furthermore,
there were no significant changes in histone 3 occupancy or
acetylation at the HIV-1 LTR in either 2D10 or J89 cells fol-
lowing depletion of cMyc and YY1 (Fig. 6). Altogether, these
data indicate that a complex network of factors is involved in
the maintenance of HIV-1 quiescence in Jurkat cells and that in
the absence of cMyc and YY1, other mechanisms maintain
recruitment of HDACs to the HIV-1 LTR.
The effect of YY1 depletion is enhanced
by HDAC inhibition
The modest effects of cMyc and YY1 depletion on HDAC
recruitment to the HIV-1 LTR were surprising because both
have previously been shown to repress transcription of the
HIV-1 LTR through HDAC recruitment. However, as ChIP
assays are only semiquantitative, an alteration of HDAC oc-
cupancy that is functionally important might not be detected.
Therefore, because RNAi depletion did not achieve complete
inhibition of protein expression and to further determine
whether cMyc and YY1 were involved in repression of the
HIV-1 promoter, 2D10 and J89 cells were treated with the
HDAC inhibitor SAHA and the effects of depleting cMyc,
YY1, or cMyc and YY1 from 2D10 and J89 cells were assayed.
Eighteen hours after the addition of a maximal concentration
of SAHA (500 nM) to cells that had been transduced with the
vector control, approximately 9.23% of the 2D10 cells were
found to be expressing GFP. However, the addition of SAHA
in combination with the depletion of YY1 significantly in-
creased the effect of YY1 knockdown and induced GFP
expression in approximately 32% of the 2D10 cells (Fig. 7,
p-value < 0.05). Because the concentration of SAHA used is
able to completely inhibit HDACs, the significant increase in
expression when SAHA is added to YY1 depleted cells
FIG. 5. Histone 3 and acetylated
histone 3 levels on the HIV-1 pro-
moter did not significantly change
following depletion of cMyc or YY1
in Jurkat cells. (a, c) Histone 3 oc-
cupancy of the HIV-1 promoter in
2D10 (a) and J89 (c) cells did not
significantly change following de-
pletion of cMyc or YY1. (b) The
levels of histone 3 acetylation sig-
nificantly increased after depletion
of cMyc in 2D10 cells. However, the
level of acetylated histone 3 did not
change following knockdown of
cMyc or YY1 in J89 cells (d) or after
depletion of YY1 in 2D10 cells (b).
*p-value of less than 0.05.
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indicates that YY1 mediates repression of HIV-1 transcription
through a non-HDAC mechanism.
Inhibition of HDACs with 500 nM SAHA did not augment
the effects of depleting cMyc or cMyc and YY1 in 2D10 cells
(Fig. 7). Furthermore, no significant changes in LTR expres-
sion were observed in J89 cells that were treated with SAHA
in combination with depletion of cMyc, YY1, or cMyc and YY1
(data not shown). This finding indicates that there are indeed
multiple mechanisms involved in the repression of HIV-1
transcription and that targeting multiple factors can result in
increased HIV-1 expression.
Discussion
cMyc and YY1 bind to the HIV-1 LTR and regulate tran-
scription through recruitment of HDACs.8,11 We sought to
determine whether selective antilatency therapy could be
specifically targeted to transcription factors that recruit
HDACs to the HIV-1 LTR. Depletion of cMyc, YY1, or cMyc
and YY1 did not significantly affect transcription or protein
levels of the HDAC proteins, which indicates that the effects
on HIV-1 transcription are not a secondary effect of changes in
HDAC expression. Depletion of YY1 resulted in a significant
increase in mRNA expression and the percentage of cells ex-
pressing GFP protein from the HIV-1 LTR in the 2D10 cells but
not in J89 cells (Fig. 3). However, in contrast to studies in HeLa
cells, single knockdown of cMyc did not have a significant
effect on transcription of mRNA from the HIV-1 LTR or on the
induction of GFP protein expression from the HIV-1 LTR (Fig.
3). Furthermore, depletion of cMyc and YY1 together did not
induce HIV-1 transcription in either cell line. As cMyc has
been show to be required for Tat-mediated elongation of the
HIV-1 promoter,14 it is possible that cMyc’s role in elongation
may account for the lack of HIV-1 transcription that was ob-
served after depletion of YY1and cMyc and may explain why
the significant increase in histone 3 acetylation did not cor-
relate with an increase in expression. Depletion of cMyc, YY1,
or cMyc and YY1, followed by activation with PMA, induced
a significant amount of expression from the HIV-1 LTR in
FIG. 6. Concurrent knockdown of cMyc and YY1 did not significantly affect HDAC1, 2, or 3 recruitment to the HIV-1
promoter or the levels of histone 3. Depletion of cMyc and YY1 from 2D10 cells did not affect the levels of HDAC1 (a),
HDAC2 (b), HDAC3 (c), histone 3 (d), or acetylated histone 3 (e) at the HIV-1 LTR. Similarly, no changes in HDAC
occupancy or histone 3 occupancy or acetylation was observed at the HIV-1 LTR following depletion of cMyc and YY1 in J89
cells (f–j) as measured by ChIP.
FIG. 7. Targeting YY1 and HDAC activity significantly
increases expression from the HIV-1 LTR. Depletion of YY1
in conjunction with the addition of 500 nM SAHA for 18 h
resulted in a significant increase in the percentage of 2D10
cells expressing GFP as compared to cells that were trans-
duced with the vector control and treated with SAHA as
measured using flow cytometry. Depletion of cMyc or cMyc
and YY1 in combination with SAHA did not significantly
increase the percentage of 2D10 cells expressing GFP. *p-
value of less than 0.05.
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2D10 and J89 cells (Supplementary Fig. S1). Therefore, we can
conclude that cMyc is not absolutely required for activation of
the HIV-1 promoter by PMA. However, because depletion of
cMyc and YY1 resulted in less activation of the HIV-1 pro-
moter than depletion of YY1 alone, the mechanism of re-
pression that is mediated by YY1 may act through a pathway
that requires cMyc. These results are particularly surprising in
light of previous studies that found disruption of cMyc or YY1
was sufficient to disrupt quiescent HIV-1 proviruses. Because
YY1 depletion did not activate HIV-1 transcription in both cell
lines, targeting YY1 as part of a future antilatency therapy
may not broadly disrupt latency in all proviral integrants.
Knockdown of cMyc, YY1, or cMyc and YY1 did not sig-
nificantly affect histone 3 occupancy of the HIV-1 LTR. Al-
though cMyc and YY1 are known to recruit HDACs to the
HIV-1 LTR in HeLa cells, the results from this study indicate
that they are not absolutely required to recruit HDAC1,
HDAC2, or HDAC3 to the HIV-1 LTR in Jurkat cells. Contrary
to previous findings, these results indicate that in T cells other
transcription factors that bind to the HIV-1 LTR may be able to
compensate for the loss of cMyc, YY1, or both and maintain
HDAC occupancy. Specifically, NF-jB and CBF1 have been
implicated in recruitment of HDAC1 to the HIV-1 LTR and
may be able to compensate for the loss of cMyc and YY1.7,9
Furthermore, these or other proteins may contribute to the
repression of HIV-1 transcription in T cells. Additionally,
these finding highlight an important difference between HeLa
cell line models of HIV-1 latency and T cell line models of
HIV-1 latency and indicate that the epigenetic environment
surrounding the HIV-1 LTR in HeLa cells may be less stable
than in T cells. Although Jurkat cells more closely resemble
primary CD4 + T cells, it is still important to develop more
advanced tools and model systems for the future study of the
epigenetics of quiescent HIV-1 proviruses.
Interestingly, targeting HDAC recruitment through de-
pletion of YY1 in conjunction with HDAC inhibition resulted
in a significant increase in GFP protein expression from the
HIV-1 promoter. This finding indicates that targeting multiple
restrictive mechanisms at the HIV-1 LTR may be an innova-
tive method for disrupting HIV-1 latency. YY1 is involved in
several malignancies and some new classes of chemothera-
peutics have been demonstrated to decrease expression of
YY1.26 Such approaches might be used for the treatment of
latent HIV-1 infection, and may be able to augment the effects
of SAHA (N. Archin, unpublished results). However, addi-
tional development of drugs that directly target the protein
interaction domains of YY1 could be pursued.
Previous studies have found that the chromatin environ-
ment surrounding the HIV-1 insertion site may affect tran-
scription. Furthermore, in vivo infected CD4 + T cells have a
range of insertion sites. To account for the effect of insertion
site differences, we performed our studies in two Jurkat cells
lines with distinct proviral insertion sites. The differences seen
between the two cells lines may be attributable to the differ-
ence in proviral locations. However, apart from the effects of
YY1 depletion, most of the results were seen in both cell lines,
indicating that the proviral location may have had only
modest effects. The differences in results found in this study as
compared to previous studies in HeLa cells highlight the
importance of conducting studies in multiple lineages of cell
lines. Although Jurkat cells are derived from CD4 + T cells,
there are still some important differences between these cells
and in vivo HIV-1-infected cells. Therefore, our laboratory and
others are working to develop models of HIV-1 quiescence
that more accurately mimic the in vivo environment of HIV-1
quiescence.
In conclusion, we find that depletion of the transcription
factor YY1 using transduction of shRNAs in Jurkat cells is
sufficient to disrupt the repression of the HIV-1 promoter in
select cellular contexts. However, depletion of the transcrip-
tion factor cMyc does not induce HIV-1 expression in Jurkat
cells. Importantly, we found that depletion of cMyc, YY1, or
cMyc and YY1 is not sufficient to disrupt the binding of
HDAC complexes to the HIV-1 LTR in Jurkat cells. There-
fore, we can conclude that the mechanism of maintenance of
HIV-1 transcriptional repression is complex and may require
a combination of therapies that target multiple levels or
several factors to reverse transcriptional repression of the
HIV-1 LTR.
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